CGT

139개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved139 programs
CGTStandard DatabasestaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleSecuraBioPhase 1

Duvelisib (Duvelisib)

Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 45Status Active
CGTStandard DatabasestaleOHSU Knight Cancer InstitutePhase 2

Hyper-CVAD (Hyper-CVAD)

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 40Status Recruiting
CGTLimited DatastaleCartesian TherapeuticsPhase 1

CAR-T (Chimeric Antigen Receptor T Cells, Chimeric Antigen Receptor T Cells (CAR-T))

B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 38Status Recruiting
CGTLimited DatastaleBeOne MedicinesPhase 2

Sonrotoclax (Sonrotoclax)

Large B-cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 38Status Recruiting
CGTStandard DatabasestaleNovartis PharmaceuticalsPhase 2

CTL019 T-cells (CTL019 T-cells)

B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 37Status Active
CGTStandard DatabasestaleNovartisPhase 3

CTL019 (CTL019)

Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 36Status Recruiting
CGTStandard DatabasestaleJuno Therapeutics, a Subsidiary…Phase 2

lisocabtagene maraleucel (JCAR017, JCAR017 (lisocabtagene maraleucel))

Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic · Leukemia, Lymphocytic, Chronic, B-Cell

#LeukemiaLymphocyticChronicB-Cell#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 34Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 30Status Recruiting
CGTStandard DatabasestaleYake Biotechnology Ltd.Phase 2

CAR-T cells targeting CD19 and CD22 (CAR-T cells targeting CD19 and CD22)

B-Cell Acute Lymphoblastic Leukemia, Adult · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Active
CGTStandard DatabasestaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Lymphoma, B-Cell · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleLiping DouPhase 2

CD22/CD19 Dual-Target CAR-T Cells (CD22/CD19 Dual-Target CAR-T Cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 15Status Recruiting
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 13Status Recruiting

1 / 7 pages

← PreviousNext →